Highlights of the TEMPO-3 Trial
Based on the results of the Phase 3 TEMPO-3 randomized clinical trial, several key findings emerge regarding the use of tavapadon as an adjunctive treatment to levodopa in Parkinson’s disease (PD). First, tavapadon achieved a statistically significant increase of 1.10 hours in daily ‘good-on-time’ (on-time without troublesome dyskinesia) compared to placebo. Second, the drug demonstrated a robust reduction in daily ‘off-time,’ with a mean reduction of 0.94 hours over the placebo group. Third, the safety profile was characterized as favorable, with most adverse events being mild to moderate, primarily consisting of nausea and dizziness. Finally, the study confirms the clinical viability of selective D1/D5 receptor agonism, providing a novel mechanistic pathway for managing motor complications in patients already receiving stable levodopa therapy.
